

STENOCARE (STENO)

Transforms to a Profitable Growth Company



STENOCARE A/S (“STENOCARE” or the “Company”) is a medical cannabis trading company with products approved and available for patients in six countries. The Company has recently launched a premium product, Astrum 10-10, which Analyst Group sees as an important growth driver in the coming years, as it distinguishes STENOCARE from competitors, providing improved, uniform and faster uptake in the blood. The product became available to patients in three countries during Q1-25, Germany, Australia, and Norway. With estimated net sales of DKK 17.2m by 2027, an applied P/S multiple of 3x and a discount rate of 14%, a potential present value per share of DKK 1.01 (0.89) is derived in a Base scenario.

Continued Sales Momentum – 11% Growth Q-Q

STENOCARE continued the Company’s positive trajectory during Q3-25, reporting net sales of DKK 1.9m, corresponding to growth of 11% Q-Q. In the comparable quarter last year, sales were negatively impacted by a return of expired products, why the net sales were negative. Compared to gross sales, the DKK 1.9m represented a 71% Y-Y increase. The growth is assumed to be attributable to strong development in Denmark, where market data suggests that STENOCARE has gained market share during 2025.

Astrum Oil Has Been Prescribed to Patients

In the Q3-report, STENOCARE mentioned that the Astrum 10-10 oil, the Company’s premium product, has been prescribed to patients in Germany. We asses that STENOCARE’s lack of strong growth internationally historically is due to a market growth that has been slower than first anticipated as well as high competition. We expect the Astrum oil to differentiate STENOCARE from competitors, hence facilitate international growth apart from the Danish market. However, we estimate only minor sales contribution from Astrum oil in 2025, as the product is expected to take time to scale and gain recognition among physicians, while we see it as the most important growth driver from 2026 and beyond.


STENOCARE 3.0 Continues to Support Profitability

For the second consecutive quarter, STENOCARE delivered a positive EBITDA of DKK 60k, up from DKK 20k in Q2-25 and DKK -3.6m in Q3-24. The improvement reflects strong revenue growth together with a substantial reduction in operating expenses, resulting from the implementation of the STENO-CARE 3.0 strategy, through which the Company has repositioned itself as a trading and product development company and consequently discontinued the cultivation operations.

Slight Upward Revision on Estimates and Valuation

Analyst Group argues that the Q3-report further confirms successful execution of STENOCARE 3.0 with growth and decreasing costs, illustrating a scalable business model as a distributor of the Company’s medical cannabis products. As a result, we have raised our estimates and valuation range slightly.


VALUATION RANGE



STENOCARE

Share Price (2025-10-23)	1.33
Shares Outstanding	38,403,745
Market Cap (DKKm)	50.9
Net cash(-)/debt(+) (DKKm)	-2.1
Enterprise Value (DKKm)	48.8
List	Nasdaq First North Growth Market
Q4-report 2025	2026-02-26

STOCK DEVELOPMENT



TOP SHAREHOLDERS (SOURCE: INTERIM REPORT)

= INSIDER

SC-Founders Holding ApS 					12.7%
HHTM ApS 					11.6%
STENOCARE A/S (Treasury shares)					0.5%
Others					75.2%
Estimates (DKKm)	2025E	2026E	2027E	2028E	
Net sales	6.5	12.9	17.2	22.4	
<i>Net sales growth</i>	<i>192%</i>	<i>98%</i>	<i>34%</i>	<i>30%</i>	
Other external expenses	-5.2	-8.2	-11.1	-14.1	
<i>Share of net sales (%)</i>	<i>-80%</i>	<i>-64%</i>	<i>-64%</i>	<i>-63%</i>	
Personnel expenses	-3.0	-3.2	-3.6	-4.3	
EBITDA	-1.6	1.5	2.5	4.1	
EBITDA margin	-25%	11%	14%	18%	
P/S	7.8	3.9	3.0	2.3	
EV/S	7.5	3.8	2.8	2.2	
EV/EBITDA	neg.	33.5	19.6	11.9	
EV/EBIT	neg.	35.3	20.2	12.2	

Introduction

Table of contents

Investment Thesis	3-4
Comment on Q3-report 2025	5-6
CEO Interview	7
Company Description	8-9
Market Analysis	10-11
Financial Forecasts	12-13
Valuation	14-15
Bull & Bear	16
Management & Board	17
Appendix	18-20
Disclaimer	21

ABOUT THE COMPANY

STENOCARE, founded in 2017, is a Danish pharmaceutical company who became the first company to receive permission to import, distribute as well as to cultivate and produce medical cannabis in Denmark in 2018. Today, STENOCARE focuses on distribution of medical cannabis and sources the products from several international suppliers, which are sold to a growing number of international markets. STENOCARE was listed on Spotlight Stock Market on October 26th, 2018 and is today listed on Nasdaq First North Growth Market Denmark since May 15th, 2020.


CEO AND CHAIRMAN

CEO	Thomas Skovlund Schnegelsberg
Chairman	Marianne Wier

ANALYST


Name	Axel Ljunghammer
Phone	+46 706 554 551
E-mail	axel.ljunghammer@analystgroup.se

Value Drivers




Medical cannabis is getting more accepted by the health care industry and legalized as a pharmaceutical medicine by authorities, which STENOCARE is expected to capitalize on. Furthermore, the Company has launched a new patented product, Astrum, which is expected to have several benefits compared to competing generic products and has the potential to disrupt the medical cannabis industry, which is estimated to drive the Company's revenue.

Historical Profitability




STENOCARE has been profitable in two consecutive quarters, which is the first time since Q1-19. The updated strategy STENOCARE 3.0 has decreased cost base, which together with revenue growth is expected to improve results further in the coming years. The rating is based on historical results and is not forward-looking.

Management & Board



The management and board of STENOCARE have broad experience within leadership, business innovation, rules and regulations as well as commercialization. Thomas Skovlund Schnegelsberg (CEO), Rolf Steno (CCO) are the co-founders and the largest shareholders in STENOCARE through SC-Founders Holding ApS who owns 12.7% of the capital and each board member holds shares, which provides incentives to create shareholder value.

Risk Profile



The cash balance amounted to DKK 4.5m at the end of Q3-25. STENOCARE's burn rate has decreased during the last quarters through the exit from cultivation activities. Nevertheless, continued sales momentum is essential to achieve a sustainable positive cash flow. Moreover, STENOCARE is dependent on products being approved by authorities, as well as accepted by the health care industry, which implies a regulatory risk.

Investment Thesis

18%
CAGR MARKET
GROWTH UNTIL
2033

Legalization are Expected to Drive Market Growth

The legal medical cannabis market in Europe has grown strongly over the last years, with several large and influential countries legalizing, such as Germany and the UK. The largest target group for medical cannabis are patients who suffer from chronic pain, but also cancer, multiple sclerosis, and epilepsy. According to data from IMARC Group, the Europe medical Cannabis market is estimated to grow at a CAGR of 18.3% from 2025-2033, leading to a market value of USD 12.7bn at the end of the forecast period. The market growth is expected to be driven by continued legalization of both medical and adult use¹. Moreover, the rising acceptance of cannabis for the therapeutic benefits mainly in chronic pain and neurological disorders is enhancing the market growth further, where STENOCARE is expected to capitalize on the growth through increased patient prescriptions.

Pharma Case on a Fast Track

The medical cannabis market in Europe is highly regulated, which makes it difficult to get products approved, both for STENOCARE and competitors. However, in the last years, STENOCARE has a proven track record of getting products approved in different markets, most recently the Astrum oil in the Australian, German and Norwegian markets during 2024 and a CBD100 oil in Denmark, proving that the Company has relevant knowledge regarding the regulatory framework and can deliver products accordingly. Hence, STENOCARE should be seen as a sort of pharma case who operates on a highly regulated market, where product approvals are difficult to reach, just like for a pharma company with a drug candidate. However, STENOCARE do not need to go through different clinical phases, i.e., phase 1, 2, and 3, like traditional pharmaceutical companies, for which it can take 5-10 years to get an approved product to market, compared to 12-14 months for STENOCARE. Hence, the Company should be seen as a pharma case on a *fast track* who relatively quickly can access new markets.

Launch of STENOCARE Astrum Oil – a Premium Medical Cannabis Oil

Today, doctors face challenges when prescribing oral medical cannabis to patients since the metabolism will reduce the uptake of cannabinoids in the body to a significantly level of approx. 15% which means that a variable, and often a small part of the cannabinoids, are actively delivered to the body with therapeutic effect. Furthermore, the body's absorption will be different depending on whether the drug is taken before or after intake of food. This causes unpredictable effects and difficulties for doctors to prescribe the right dosage. STENOCARE has introduced a new patented oil to address these challenges – Astrum oil - which the Company has global exclusivity to use for medical cannabis. A study from September 2022 showed positive results on dogs, indicating that the Company's Astrum oil substantially enhances the uptake of cannabinoids, regardless of meal consumption and inter-individual biological differences.

The patented Astrum oil has been launched in Germany, Australia and Norway. Germany and Australia are two of the larger medical cannabis markets globally, and expansion to more countries are expected in the future. With this launch, we see STENOCARE as a first mover in next generation medical cannabis oil products, which is expected to make the Company gain an advantage against potential competitors. Considering the advantage from using the Astrum oil, as well as the fact that the product is expected to address a global market, this is expected to drive strong revenue growth for STENOCARE ahead.

LAUNCH OF
ASTRUM IN IN
THRE MARKETS
DURING Q1-25



STENOCARE ASTRUM OIL
ENABLE:



Improved uptake in the
blood..



.. individuals reaching
maximum concentration of
the drug in the blood
faster..



..as well as getting the
same concentration in the
blood regardless if the
patient has eaten
or has fasted.



¹Adult use refers to usage
other than medical

Investment Thesis

Several Products Approved for Sales in Denmark



During Q1-24, STENOCARE announced that a balanced oil, called “THC/CBD Olie STENOCARE” has obtained approval by the Danish Medicines Agency. With the approval, STENOCARE has regained the Company's position to be a provider of all three essential oil products in Denmark; THC oil, CBD oil, and now also the new THC/CBD oil. Back in 2018/2019, STENOCARE had the three products on the market but after switching supplier, the products needed to obtain approval again by authorities, which has now been completed. After increased competition and price pressure hampered sales during H2-24, STENOCARE has regained sales momentum in Denmark during 2025, with increased sales of the THC/CBD oil product. This product has historically been STENOCARE's most important product regarding sales, why we see positively on the regained momentum, which suggests that STENOCARE is gaining market share in Denmark.

Moreover, STENOCARE obtained approval for a new medical cannabis oil, CBD100, during Q4-24 in Denmark, which has higher concentration of CBD (100 mg/ml). The new CBD oil provides doctors in Denmark with an additional option for treating these symptoms, as STENOCARE becomes the sole supplier of medical cannabis oil products with such a high concentration of CBD, which, according to Analyst Group, constitutes a competitive advantage. The launch has been successful initially as the growth during 2025 is assumed to be partly driven by the CBD100 oil.

Launch of an IT-platform to Inform and Help the Industry

STENOCARE has developed an IT-platform that enable doctors to launch and operate online clinics, wherever they are. This is expected to increase a doctor's reach to patients and facilitates patients' access to trained and experienced doctors. The platform will support doctors through easier administration, for instance patient booking, video consultation and patient journal, training, supervision by, and ongoing access to the STENOCARE medical consultant and specialists as well as cost efficiency. The European Pain Federation currently estimates that there are 150 million people who are experiencing chronic pain in Europe, yet, for instance, 1.8 million people in the UK are thought to buy cannabis illegally for self medication instead of getting a prescription. A threshold that holds the market growth back is that patients have limited access to prescribing doctors. Analyst Group believes that STENOCARE's online platform can enable doctors to increase their geographical reach and thus increase patients access to medical cannabis.

Forecast and Valuation: a Summary

STENOCARE is expected to grow sales from DKK 2.2m in 2024 to 22.4m in 2028, corresponding to a CAGR of 78%, based on strong market growth driven by deregulations, a pharma mindset that doctors and authorities appreciate and the launch of the premium product Astrum oil in 2025. Based on a target multiple of P/S 3x applied on estimated sales of DKK 17.2m in 2027, and an internal rate of return of 14%, which accounts for the time specific risk of events that are far away and have not yet occurred, as well as the likely high demand for return that an investor have when investing in STENOCARE, this yields, in a Base scenario, a net present value per share of DKK 1.01.

Highly Regulated, Slow-moving Market and Financial Position Poses a Risk

The European medical cannabis market is highly regulated, STENOCARE is thereby required to obtain and maintain appropriate licenses to manufacture, import and sell its products. Although the Company has a strong track record of getting approvals in different markets, there is a risk that STENOCARE will not receive the necessary permits from authorities in new potential markets. Additionally, STENOCARE is dependent on doctors prescribing medical cannabis to patients, where there has been a stigma surrounding cannabis as medicine historically, making the market slow-moving. The Company addresses this issue by educating doctors on medical cannabis and having consultants available to answer doctors' questions.

The cash balance amounted to DKK 4.5m at the end of Q3-25 and STENOCARE's burn rate has decreased during the past quarters due to the exit from cultivation activities, where continued sales growth is expected to improve the cash flow further going forward. However, from July 2025, the convertible debt, originally amounting to DKK 2.8m (DKK 2.4m at the end of Q3-25), will be repaid in equal monthly instalments over 18 months, corresponding to approximately DKK 0.16m per month. Nevertheless, based on the estimated sales growth and decreasing cost base, we asses that STENOCARE's financial position is stable. However, if the scale-up of Astrum oil is delayed, positive cash flow would materialize at a later point, meaning the potential need for additional external capital cannot be excluded.

INCREASED
PATIENT ACCESS
THROUGH IT-
PLATFORM

DKK 22.4M
REVENUES 2028E



Comment on Q3-Report 2025

Continued Sales Momentum

11%
GROWTH Q-Q

Q3-25 marked another strong quarter for STENOCARE, where net sales amounted to DKK 1.9m, corresponding to a growth of 11% Q-Q. The third quarter last year was negatively affected by returns of expired products, leading to net sales amounting to DKK -0.9m, why net sales grew by DKK 2.8m in Q3-25. Excluding the expired products, gross sales amounted to DKK 1.1m in the comparison period, why the Q3-25 net sales marks a 71% growth compared to gross sales in Q3-24.

The growth points towards that the special situation with a competing magistral product being supported with 85% patient subsidy from the Danish Medicines Agency compared to STENOCARE's 50%, that affected sales in H2-24, has been solved and market data suggests that STENOCARE has gained market share in Denmark during 2025, Denmark is assumed to be the main contributor to the growth in the last quarters. When comparing to Q3-24, it should also be noted that STENOCARE are using a new more conservative revenue recognition method, where revenues is now recognized when products are sold to the end-user. Previously, revenue was recognized when products were sold to distributors.

In terms of products, STENOCARE's THC/CBD oil product, which has been available since Q2-24, and the new CBD100 oil product, which has been available since the end of Q1-25, are assumed to be the main drivers of the growth.

ASTRUM IS
EXPECTED TO BE
A KEY GROWTH
DRIVER

As Analyst Group has previously stated, the Company's premium product, Astrum 10-10 oil, is viewed as a key growth driver throughout the coming years. The product differentiates STENOCARE as a first mover in the next generation of medical cannabis, providing improved, uniform, and faster uptake in the bloodstream. Astrum oil became available to patients in three countries during Q1-25: Germany, Australia, and Norway. The product is currently being prescribed to patients in Germany, where STENOCARE's local partners are actively working to educate the market about its advantages. However, Astrum oil is not yet assumed to have contributed significantly to sales growth in 2025. The introduction of new products typically takes time, as the European medical cannabis market remains relatively young, and both the market and prescribing physicians require further education on the products' benefits — an area in which STENOCARE is actively engaged.

Nevertheless, the product is now gaining traction, and STENOCARE has received encouraging feedback from the market. We therefore expect a gradual increase in sales over the coming periods, which, together with the strong momentum in Denmark, provides favorable conditions for continued growth in 2026.


Positive EBITDA result and Operating Cash Flow

DKK 60K
EBITDA RESULT
IN Q3-25

For the second consecutive quarter, STENOCARE reported a positive EBITDA result, amounting to DKK 60k, compared to DKK 20k during Q2-25 and DKK -3.6m during Q3-24. The positive EBITDA is driven by strong sales growth combined with a significant cost reduction, achieved through the new STENOCARE 3.0 strategy, under which the Company has repositioned itself as a trading and product development business for medical cannabis and consequently exited its cultivation activities. Through the updated strategy, operating expenses decreased by -38% during Q3-25, amounting to DKK 1.9m (3.0). It should also be mentioned that cost of goods sold (COGS) is included in the operating expenses, which is assumed to have grown Y-Y in line with the sales growth, suggesting that the underlying cost reduction is even greater than the reported 38% decline. The cash flow from operations amounted to DKK 0.06m (-1.9), in line with the improved result.

STENOCARE's cost base has decreased in the last year following the exit from cultivation.

Operational expenses, Q2-23-Q3-25



Source: STENOCARE quarterly reports

Comment on Q3-Report 2025

DKK 4.5M CASH POSITION AT THE END OF Q3-25

Stable Cash Position

The cash position at the end of Q3-25 amounted to DKK 4.5m, which can be compared to DKK 4.9m at the end of Q2-25, where the negative cash flow of DKK -0.4m is entirely attributable to repayment of STENOCARE's convertible debt. From July 2025, the convertible debt, originally amounting to DKK 2.8m (DKK 2.4m at the end of Q3-25), will be repaid in equal monthly instalments over 18 months, corresponding to approximately DKK 0.16m per month. The loan also carries the option to be converted into shares at a price of DKK 4.29 per share.

In light of this obligation and the current cash position, maintaining the sales momentum and cost control is considered essential to achieving positive cash flow, which Analyst Group expects to be supported by continued growth in Denmark and the launch of Astrum oil in three additional markets during Q1-25.

However, continued growth could come at a cost, both in terms of marketing investments, such as ongoing education of the industry, and increased working capital, which, in addition to a slower growth rate, could have a negative impact on cash flow. STENOCARE is now considered to be in a position where the Company can choose to accelerate or hold back on investments depending on market opportunities and available capital. Given this, as well as the expected amortization of the loan, it cannot be ruled out that STENOCARE may require additional capital to boost the Company's growth journey. Such a need is, however, expected to be limited and could likely be managed through, for example, raising a new loan, as the Company remains debt-free apart from the mentioned convertible debt instrument.

74% Y-Y GROWTH IN CANNABIS IMPORTS IN AUSTRALIA

Strong Growth Momentum in the Australian Medical Cannabis Market...

Recently published data in Australia shows continued rapid expansion during last year, where total cannabis imports increased 77.4 tons, a 74% growth Y-Y, making it one of the fastest-growing markets globally. Like many other countries growth has been largely driven by telemedicine prescriptions. Prescription data from the Therapeutic Goods Administration (TGA) shows chronic pain as the leading indication, followed by anxiety and sleep disorders. THC-dominant products remain the most prescribed category, while CBD-based treatments are gaining traction for mental health-related conditions. STENOCARE are present in Australia with a balanced THC/CBD-oil since 2022 and during 2025, the Astrum 10-10 oil has been launched in the country. STENOCARE's sales in Australia have progressed more slowly than initially anticipated. However, the launch of Astrum oil is expected to create new opportunities for the company to capitalize on the rapid market growth through a differentiated product offering compared to competitors.

...but Stricter Prescription Rules may Hinder Growth in the German market

Germany's medical cannabis imports have surged to record levels in 2025, but growth may slow as the government introduces stricter prescription rules. The proposed law would limit telemedicine by requiring initial in-person consultations and uphold the ban on mail-order delivery, forcing patients to collect prescriptions at pharmacies. Authorities argue that import growth is driven by excessive online prescribing, and the reform aims to tighten control over the market. Nevertheless, STENOCARE are focusing on a pharmaceutical approach and educating doctors regarding medical cannabis and even though the overall market growth is expected to slow down, this is expected to primarily harm competitors and be an opportunity for STENOCARE to gain market share, primarily through the Astrum oil as well as focusing on a pharmaceutical approach.

Nevertheless, STENOCARE's expansion in Germany has progressed more slowly than initially expected since entering the market in 2023, reflecting the high level of competition. However, with the Astrum oil launched in January 2025, the Company is now positioned as a first mover in the next generation of medical cannabis products. The oil's improved consistency and faster absorption are expected to differentiate STENOCARE from competitors and serve as a key driver for renewed growth in the German market, where the product has been prescribed for patients during Q3-25.

In conclusion, Analyst Group views STENOCARE's Q3-25 report as another confirmation of the Company's operational momentum and successful execution of the STENOCARE 3.0 strategy. The continued growth in Denmark demonstrates sustained market demand and recovery following previous market challenges. Meanwhile, Astrum oil, launched across three international markets, is expected to become an increasingly important growth driver in 2026 as market adoption advances. Moreover, the second consecutive quarter of positive EBITDA and operating cash flow highlights the improved cost structure and scalability of the business model. With expanding international presence and a differentiated product portfolio, STENOCARE is well positioned for continued profitable growth going forward.

CEO Interview, Thomas Skovlund Schnegelsberg



As you recently published the Q3 report for 2025, how would you summarize the quarter? What are you extra satisfied with and is there something that you think you could have done better?

For STENOCARE the third quarter was another strong quarter. We grew sales and continued delivering a positive EBITDA for the second quarter in a row. We see this as the best quarter since 2019. Historically, the third quarter has been “quieter” because of the Summer holiday season, but we are very satisfied that we have seen “all time high” sales during this period. We would have liked to see more traction in the German market. The local health authorities are currently overwhelmed with work, and this is slowing down some of our initiatives in Germany. But we expect this is a temporary situation and pace will very soon increase.

You delivered a positive EBITDA result for the second consecutive quarter as well as positive operating cash flow during Q3-25. How do you intend to balance more growth-driving initiatives with continuing to strengthen profitability going forward?

In the third quarter we see a full quarter with all 4 approved oil products in the Danish market. We see an increasing demand from patients and expect sales in Denmark to increase. Sales of our Astrum oil product in Germany and Australia is just beginning and we expect sales of this product with significant competitive advantages also to increase in the coming quarters and years. In combination with increased sales and a continued lean organization and cost structure we expect the operational cash flow to drive growth and profitability.

You mentioned in your Q3-report that Astrum 10-10 is being prescribed for patients in Germany. What is the status for the product in the remaining two countries where the product is available, Australia and Norway?

Our efforts during Q3 have been focused on Germany, and we will very soon see the impact of all this work. Norway is a small market, and we have a good coverage of the market with our local partners. This will continue evolving slowly as expected. For Australia we initiated several activities during Q2 to position Astrum as a new category we have branded a “drink additive”. This is creating local awareness and with our Australian partner, we are educating health professionals with this new value proposition.

In Germany, following the 2024 legalization of medical cannabis, the government is now tightening regulations on online and mail-order sales. How do these regulatory changes affect your commercial model and what, if any, implications do they have for your anticipated sales growth in the German market?

In Germany there have been a growth in online prescriptions which the Government find is bordering recreational cannabis consumption. This is primarily with dried cannabis products, that is typically vaped. With our Astrum oil product, we are targeting a very different part of the market. Therefore, we might see some patients changing from dried products to oil products, which will benefit our product category.

Lastly, what would you like to highlight as particularly interesting for an investor to monitor regarding STENOCARE going into 2026?

The key aspects to follow are our continued growth in our home market. The STENOCARE 3.0 strategy has laid the foundation to further expand our foothold. The Astrum oil products will see its breakthrough and will become a significant revenue driver for Stenocare. All this will translate into a positive EBITDA for the full year.

October 24th, 2025

Company Description



PHARMA
MINDSET

STENOCARE operates within the medical cannabis industry and entered the Danish market in connection to the legalization of medical cannabis in Denmark through the *Danish Pilot Program*, launched January 1st, 2018. The program, which was a four year “trial-program” and extended with four more years, enabled doctors in Denmark to prescribe cannabis for medical use and for companies to cultivate, produce, import and distribute medical cannabis. During Q4-24, the Danish government decided on permanent legalization of medical cannabis, which will enable continued treatment with medical cannabis for patients and provide clarity regarding the future of the industry in the country. STENOCARE was the first company in Denmark to receive approval from the Danish Medicines Agency for both cultivation, production as well as distribution and import during 2018. Today, STENOCARE has a partnership with several suppliers, and has entered a total of six markets with products approved.

STENOCARE is to be considered as a sort of a pharma company, rather than a “cannabis company”, meaning the Company carefully evaluates local regulations and produces products with that in mind. As STENOCARE is convinced that EU regulations require indoor cultivation, rather than green houses, the Company are working with high quality suppliers who offers indoor cultivation.


Revenue Model

STENOCARE's revenues each year are based on the number of patients being treated, how many treatments each patient get, and income per product sold. The Company imports white label products from its suppliers, from where the products are delivered to STENOCARE's central distributors in different countries. The Company has contracts with leading distributors in each country, as medical suppliers are not allowed to sell and deliver directly to pharmacies. Instead, local distributors are providing STENOCARE's products in each country. Due to a new revenue recognition method from Q1-25, revenues are now recognized as products are sold to patients compared to before when revenues were recognized when products were sold to distributors, to minimize the risk of reversed revenue from expired products.

When a patient suffers from a condition that medical cannabis can mitigate, a doctor decides whether to prescribe medical cannabis from STENOCARE, which is later retrieved at the pharmacy by the patient. Hence, the Company's revenue is dependent on doctors' prescriptions, as well as if the patient wish to be treated with medical cannabis. Whether the patient pay for STENOCARE's medical cannabis products themselves or could obtain subsidies from the local government or insurance companies differs from market to market, as per the table to the left. The fact that the subsidies differ is expected to lead to various prescription rates as patients in countries with a higher subsidy is expected to be more likely to “buy” STENOCARE's products. Regarding the number of treatments per patient, one bottle of STENOCARE's medical cannabis oil is expected to be enough for one month of medication for the average patient. As some diseases are chronic, such as chronic pain and multiple sclerosis, STENOCARE is expected to deliver twelve product units per year to these patients. However, other diseases, such as nausea caused from cancer treatment, is expected to need fewer product units per year.

	50 % SUBSIDY FROM THE GOVERNMENT
	100 % SUBSIDY FROM THE GOVERNMENT
	100 % SUBSIDY FROM THE GOVERNMENT ¹
	0 % SUBSIDY FROM THE GOVERNMENT
	0 % SUBSIDY FROM THE GOVERNMENT
	100 % REIMBURSEMENT FROM INSURANCE COMPANIES

Illustration of STENOCARE's Supply Chain From Cultivation to Patient.



Source: STENOCARE and Analyst Groups Illustration

¹100% subsidy via hospitals or 0% subsidy via private clinics

Company Description

The Products

STENOCARE's product portfolio consists of three different products, CBD oils, THC oils, and a balanced oil, which is a mix of CBD and THC, where each product needs to be approved in each individual country. The key difference between CBD and THC oil is that THC has psychoactive effects while CBD does not. Whether a patient should be treated with a CBD oil, THC oil or a balanced oil is up to the doctor and depends on the symptoms of the patient. Medical cannabis can be used for several different conditions where chronic pain, multiple sclerosis, cancer and epilepsy are among the most common. THC has properties that can reduce nausea, which can arise in cancer treatment, while CBD has a dampening effect on cramps, and a combination can provide efficacy to patients suffering from pain.

STENOCARE has launched the Company's own premium product, the STENOCARE Astrum oil, which is a patented medical cannabis oil that enhances the uptake of cannabinoids, regardless of meal consumption and individual biological differences. With other oil-types, each patient's body reacts in their own individual way, causing troubles for doctors to predict the impact. The human body absorbs a large part of the cannabinoid, up to 85%, which means just a small part are actively reaching the patient's blood for therapeutic effect. Furthermore, the uptake is affected by the patient's intake of food, further causing problems for doctors to determine the right dosage. The goal with the STENOCARE Astrum oil is to reduce the effect of individual uptake due to biological differences, as well as food intake, when using medical cannabis, making the product more predictable. The product is now approved and available for patients in the Australian and German market, two of the larger global medical cannabis markets, as well as the Norwegian market.

Cost Drivers

STENOCARE reports two main costs in their P&L, "other external expenses" and "personnel expenses". The Cost of Goods Sold (COGS) are included in the external expenses and consist of what STENOCARE is paying their suppliers. Additionally, external expenses is expected to consist of overhead costs such as accounting, office and listing costs, which are all fixed costs. The Company's personnel expenses has been slimmed throughout 2023 and 2024 to adjust the cost base to the sales levels. Moreover, further decreases are expected from 2025 after exiting the Company's cultivation operations.

Strategic Outlook


During Q4-24, STENOCARE announced the new STENOCARE 3.0 strategy, which focuses solely on distribution of medical cannabis, hence refocus all resources, staff and investments towards succeeding with sales and product development of prescription-based products and exit all cultivation activities.

STENOCARE invests in building four assets that supplement each other and are important for the success of the Company. The four assets are 1) *Regulatory Assets*, 2) *Commercial Assets*, 3) *Partnership Assets* and 4) *Supply Chain Assets*. One important factor for STENOCARE to be able to scale up sales is to ensure the health care industry's interest and thus that doctors are willing to prescribe medical cannabis to patients. STENOCARE is expected to address *Key Opinion Leaders* (KOL) in new markets who sees medical cannabis as a positive supplement to existing treatments. In that way, STENOCARE can identify which product that is best suited for a particular market. Doctors are more used to oil products than for example dried cannabis, which is used for smoking, and thus in general are perceived more harmful, why doctors are more likely to prescribe oil products. Furthermore, given that doctors appreciate the effect of the products, a word-of-mouth effect could be possible where doctors recommend STENOCARE's medical cannabis oil products. Finally, STENOCARE has established sales channels and distribution logistics in multiple markets for prescription-based medical cannabis, which enables sales in several diverse markets. All this is the *Commercial Assets* that the Company is building.

The *Partnership assets* is about working with pharma-grade partners to develop future medical cannabis products, for example the partnership with Pebean Pharma to develop the Astrum oil. Future sales also rely on STENOCARE's supply situation and since the Company has several suppliers today, this is assumed to be enough to meet the estimated demand for the coming years, the *Supply Chain Assets*. Furthermore, market access will be of great importance for STENOCARE's future development. Being on six markets today, STENOCARE has proven the Company's ability to access new markets and adapt to different markets regulations. Each country has their own regulations which poses a challenge, why STENOCARE need to adjust their products slightly in each market to get them approved, which the Company have done successfully historically, this is the *Regulatory Assets*.

NEXT GENERATION PREMIUM PRODUCT ASTRUM OIL IS READY FOR SALES

"RECRUITMENT" OF DOCTORS IS A CRITICAL FACTOR



Market Analysis

150 MILLION PAIN PATIENTS IN EUROPE


Untouched Market With Large Market Growth Potential

The most common symptom where medical cannabis is used for treatment is chronic pain. The European Pain Federation currently estimates that there are 150 million people who are experiencing chronic pain in Europe. Other diseases where medical cannabis can be useful as a treatment to relieve symptoms is cancer, multiple sclerosis and epilepsy. According to WHO, the estimated number of new cancer treatments in Europe was 4.4 million in 2020 and it has been estimated that over 6 million people suffer from epilepsy.¹ Hence, one could argue that it is likely that a rise in demand for medical cannabis products is expected throughout a large number of countries. Since Canada introduced the medical cannabis program in 2016, several forms of legalizations have occurred in the European market. Several large and influential countries, such as Germany and the UK, have legalized and introduced the medical cannabis market, and more countries are expected to follow. Furthermore, Germany has legalized adult use in 2024 under a pilot program, which is expected to be a driver for more countries to ease regulations and a step towards greater acceptance of medical cannabis as well. However, the European market for cannabis-based products is still young, and there are significant variations in the legislative frameworks of different European countries. The different rules and regulations according to the European Pharmacopeia, such as no pesticides, quality and uniformity, makes it very difficult for medical cannabis companies to navigate the European market. Despite this, STENOCARE has managed to enter the Danish market, twice, along with the UK, Swedish, German, Norwegian and Australian market.

~50 Countries Worldwide are in Favour of Cannabis for Medical use.

Countries where cannabis for medical use is approved and countries accessed by STENOCARE

- Approved medical use
- Approved medical use in 42 of 50 states
- Nonapproved for medical use
- 📍 Countries already accessed by STENOCARE



Medical Cannabis has Benefits Compared to Opiates

The most common use of medical cannabis worldwide is for pain control. Cannabis has shown to be effective for treating chronic pain that troubles millions of individuals.² Medical cannabis can supplement and reduce the use of opiates as a safer option as it is less addictive and more difficult to overdose. Furthermore, it can also supplement NSAIDs (Non-Steroidal Anti-Inflammatory Drugs), commonly used to relieve pain and bring down high temperatures. Moreover, the illegal market for cannabis can also be considered a sort of competitor for STENOCARE in terms of treating chronic pain. For instance, 1.8 million people in the UK are thought to buy cannabis illegally on the “street”, as it does not require a prescription from a doctor and is also cheaper than buying from a pharmacy.

Medical Cannabis Made Legal Permanently in Denmark

The Danish Parliament has passed legislation making the country’s medical cannabis program permanent, effective January 1, 2026. The new law ensures the continued legal availability of medical cannabis for patients and provides long-term regulatory clarity for the industry. Analyst Group views this development as a positive for STENOCARE, as it establishes a clear framework for future operations in Denmark. The Company is believed to have a strong brand presence among medical professionals in the country, which supports the potential for further market growth.

¹ Source: Epilepsy Alliance Europe, 2011

² Source: Harvard Health, 2020


Market Analysis

Strong Expected Market Growth


The European medical cannabis market is expected to grow between 20-60% yearly over the coming years according to various market analysts. According to data from Prohibition Partners from 2023, legal cannabis sales in Europe are expected to grow with a CAGR of 43% from 2023-2027 and amount to EUR 2.2bn at the end of the forecast period. Another source, IMARC Group estimates that the Europe medical Cannabis market will grow at a CAGR of 18.3% from 2025-2033, leading to a market value of USD 12.7bn at the end of the forecast period. The market growth is expected to be driven by a continued legalization of medical use, but also adult use. Today, Germany is the largest market in Europe regarding medical cannabis and constitutes over 50% of the European market and is expected to grow to USD 1.2bn in 2028. Larger countries, like Germany and the UK for instance, are expected to grow at a faster pace owing to the progress of legislation and the large potential patient populations in these countries. STENOCARE is also active on the Australian market, which is expected to grow to USD 1.2bn in 2028, corresponding to a growth CAGR of 20%.¹

Legal cannabis sales in Europe are expected to grow with a CAGR of 43%, according to Prohibition Partners.

Sales of legal cannabis in Europe in 2023-2027
EURbn




Source: Prohibition Partners 2023



Source: IMARC Group 2024

Different medical cannabis products



Why Doctors Start to Appreciate oil Based Cannabis Products

The evolution of cannabis products can be categorized into the following; 1st generation products, such as dried flowers for smoking, and 2nd generation products, containing oil, tablets, and pills. The 1st generation products are still a significant part of prescribed products in the global market. However, doctors are more familiar and comfortable with medicine that is delivered to patients with traditional dosage methods like an oral syringe or capsules. It is expected that there is a growing demand for these methods, and especially for oil products that are dosed with an oral syringe. The benefit of this is that dosage delivery and titration, i.e., scaling the dosage volume to each patient, is easier and well known.

Deregulations in Germany and the US Reduces the Stigma Around Cannabis

Germany has legalized cannabis for adult use, where cannabis also has been removed from the list of narcotics, something that is expected to simplify the process for more doctors to prescribe medical cannabis and ease the way for patients to obtain a prescription. This is expected to support the growth of the German medical cannabis market, which is already the largest in Europe with approximately 230,000 patients. The German medical cannabis market has grown strongly during the last years, for the full year 2024 medical cannabis import more than doubled to 70 tons, up from 32 tons in 2023 and in Q2-25, imports grew by 15%

A large portion of the market growth has been driven by the rapid expansion of telemedicine clinics, which has raised concerns that the ease of access to medical cannabis has allowed individuals who do not actually require medication to gain access to medical cannabis. As a result, the government has implemented stricter prescription rules, which limits telemedicine by requiring initial in-person consultations and uphold the ban on mail-order delivery, forcing patients to collect prescriptions at pharmacies. Authorities argue that import growth is driven by excessive online prescribing, and the reform aims to tighten control over the market.

Nevertheless, STENOCARE focuses on prescription based medical cannabis and has long focused on educating doctors on potential applications. Since January 2025, Astrum oil has been available to German patients, and we expect the product's benefits to drive sales to patients in need of medical cannabis treatment, regardless of political initiatives that may hinder overall market growth.

Financial Forecast

353%
NET SALES
GROWTH DURING
2025

200,000
PATIENTS ON THE
AUSTRALIAN
MARKET

DKK 22.4M
NET SALES 2028

Revenue Forecast 2025-2028


During 2025, STENOCARE has shown strong momentum with net sales growth amounting to 353% for the first nine months, attributable to a strong performance in Denmark. This suggests that the previous higher subsidy for the competing products, where a competing magistral product being supported with 85% patient subsidy from the Danish Medicines Agency, compared to STENOCARE's 50%, has been reversed or that STENOCARE's products are delivering more value to patients, hence are taking market share despite a lower subsidy. This bodes well for future estimated growth according to Analyst Group, as the Danish market historically has been STENOCARE's most important.

Regarding international markets the growth has been lower than first anticipated. The sales development has been slower than estimated on the UK market, as a result of a more sluggish market. The sales in Germany has also been lower than estimated despite a fast-growing medical market. However, STENOCARE has launched the Company's premium product, the Astrum oil, which is available in Australia and Germany, two of the largest markets globally, as well as Norway. The Australian medical cannabis market has grown to over 200,000 patients, which can be compared to Europe's largest market Germany with approximately 230,000 patients, showcasing the market potential in these countries. The product has obtained approval for reimbursement in Germany through major health insurance providers, which is seen as a pivotal step toward accelerating product growth in the largest European market. Astrum oil has unique characteristics compared to other medical cannabis oil products and has the potential to revolutionize the industry, why the product is expected to be an important sales driver for STENOCARE.

For Q4-25, we expect continued sales momentum in the Danish market to remain the primary growth driver. STENOCARE's balanced oil in Denmark has historically been the Company's most important product in terms of sales, and we estimate continued strong demand for this product going forward. In addition, the newly launched CBD100 oil, available to patients since the end of Q1-25, has gained traction as the only product of its kind and is also expected to contribute to growth in 2025. Furthermore, the launch of STENOCARE's premium product, Astrum oil, in Australia and Germany is viewed as a key growth driver. However, we anticipate a larger contribution from Astrum oil in 2026, as the product is expected to take time to scale and gain recognition among physicians, given that it was only launched during Q1-25 across all three markets. Given the advantages with the product and that we expect the product to obtain approval in more markets, we expect the Astrum oil to be a significant growth driver in the long run.

For the full year 2025, we estimate net sales of DKK 6.5m, corresponding to a growth of 192%. In 2026, Analyst Group expects continued strong growth in net sales of 98%, primarily driven by continued momentum in Denmark as well as strong development fort Astrum oil, resulting in a revenues of 12.9m. The market growth is expected to be driven by legalizations and since larger, and more influential countries, for example the UK and Germany, have legalized medical cannabis, it is expected to be considered more accepted as a treatment by doctors, which is estimated to contribute to the sales growth during the forecast period. In 2027 we estimate net sales of DKK 17.2m, corresponding to a growth of 34% and in 2028 we estimate net sales of DKK 22.4m, corresponding to a growth of 30%.

Revenue is expected to grow at a rapid pace.



Source: Analyst Group estimates

Financial Forecast

STENOCARE 3.0
REDUCES THE
COST BASE


Operating Expenses 2025-2028

STENOCARE has aggregated several cost items into one post, external expenses, which, together with personnel expenses and depreciation, are the only expenses reported on an operational level. External expenses have been the largest costs historically, where expenses for STENOCARE's own cultivation facility as well as COGS is assumed to be the largest driver. In 2023 and 2024 STENOCARE decreased the cost base to operate with a lean organization. With the announced updated STENOCARE 3.0 strategy where the Company has exited the production activities while focusing on distribution of medical cannabis, the Company is expected to save approx. DKK 14m in financial obligations in the upcoming six years, with additional approx. DKK 5m annually saved for production staff and operating costs. Hence, we estimate a significantly reduced cost base in the upcoming years.

Naturally, STENOCARE's COGS are expected to increase as revenues are growing, hence, increasing external expenses. Analyst Group estimates STENOCARE's cost per product based on more mature, North American companies in the medical cannabis industry, such as Cresco Labs and Green Thumb Industries, where the gross margin amounts to approx. 50-55%. Analyst Group estimates a gross margin in the higher part of the interval, due to higher margins from STENOCARE's premium products, since they are expected to have a higher degree of uniqueness, leading to a higher pricing power.

All in all, external costs has decreased in 2025 through the cost savings from the STENOCARE 3.0 strategy but are thereafter estimated to grow as revenue is expected to grow in tandem during the forecast period. Regarding personnel, STENOCARE is expected to be able to scale up sales with the current workforce with the new strategy as a trading company. Compared to 2024 the number of employees has decreased as the culti-vation facility has been sold. This causes personnel expenses to decrease from DKK 5.8m in 2024 to an estimated DKK 3m in 2025 and then growing to DKK 4.3m in 2028. The Q2 and Q3-reports for 2025 has validated the STENOCARE 3.0 strategy as the Company managed to grow net sales strongly while reducing the cost base, resulting in a positive EBITDA result. With STENOCARE 3.0, we expect the Company to operate with a scalable business model and with the estimated sales growth in the coming year, STENOCARE is estimated to strengthen the EBITDA margin from negative in 2025 to 18% in 2028.

External Expenses are Expected to Grow With Increased Sales, Albeit at a Lower Pace.




A Summary of Analyst Group's Financial Forecasts for STENOCARE.

Financial forecasts, 2023-2028E, Base scenario

Base scenario (DKKm)	2023A	2024A	2025E	2026E	2027E	2028E
Net Sales	4.0	2.2	6.5	12.9	17.2	22.4
Other income	0.0	0.0	0.0	0.0	0.0	0.0
Total income	4.0	2.2	6.5	12.9	17.2	22.4
Other external expenses	-10.2	-7.7	-5.2	-8.2	-11.1	-14.1
Personnel expenses	-6.4	-5.8	-3.0	-3.2	-3.6	-4.3
Special items ¹	0.0	-13.1	0.0	0.0	0.0	0.0
EBITDA	-12.6	-24.2	-1.6	1.5	2.5	4.1
EBITDA margin	-315%	-1086%	-25%	11%	14%	18%

Source: Analyst Group estimates



Valuation

Valuation: Base Scenario

In the valuation of STENOCARE a comparison with other companies within the medical cannabis industry on both the European as well as the North American market is made. As the market still is in its early days, the peer group in Europe, like STENOCARE, are to be considered as young, and in some cases small companies facing a potential rapid growth, while the North American companies are at a more mature stage, already generating substantial sales. Moreover, in general, the companies in both Europe and North America are currently unprofitable, why the valuation will be derived from a P/S multiple applied on 2027's estimated sales for STENOCARE. Although the comparison companies in both Europe and North America differ from STENOCARE in terms of business model, target market, profitability potential, and if they address medical or recreational cannabis, Analyst Group believes that the comparison provides an indication of how the market currently values companies in the cannabis sector.

	Market cap (DKKkm)	Revenue (LTM, DKKkm)	Revenue growth Y-Y	Gross Margin	EBIT (LTM, DKKkm)	P/S (x)
 DanCann Pharma	3.5	4.6	-41%	33%	-8.6	0.7
 can	347.3	383.9	118%	n/a	n/a	0.9
 SYNBIOTIC	143.3	118.7	308%	n/a	-15.7	1.2
 Cannabis Poland S.A.	23.5	0.0	-60%	n/a	-3.4	603.1
 HEMP HEALTH&	25.9	0.2	-12%	n/a	-2.5	146.9
 ODI Pharma	16.1	2.1	-86%	27%	-3.7	7.6
Average	93.3	84.9	38%	30%	-6.8	126.7
Median	24.7	3.4	-26%	30%	-3.7	4.4
 STENOCARE®	50.9	5.7	154%	n/a	-10.2	9.0

STENOCARE and the above companies are similar in relation to that they all operate within the European medical cannabis market, which is expected to show strong growth in the coming years. However, Analyst Group anticipates that the low sales and unprofitability among European cannabis companies is a result of a highly regulated and historically slower-than-expected market growth and the low reported sales to date results in high P/S multiples. P/S multiples for companies in early development or a high-growth phase are generally high, due to initially low, or zero sales. Over time, as sales increases, multiples tend to normalize in line with the company reaching a larger market share and a higher degree of maturity. Consequently, a comparison with larger, more mature companies on the Canadian and US market is also made, to investigate sector valuations in a more mature stage of a company's life cycle.

	Market cap (DKKkm)	Revenue (LTM, DKKkm)	Revenue growth Y-Y	Gross Margin	EBIT (LTM, DKKkm)	P/S (x)
 AURORA	1,823	1,644	25%	48%	-74	1.1
 CANOPY GROWTH	2,651	1,253	-16%	n/a	-722	2.1
 CRESCOLABS	2,463	4,404	-8%	50%	485	0.6
 Jushi	813	1,648	-12%	42%	0	0.5
 ORGANIGRAM	1,470	1,028	51%	33%	-95	1.4
 curaleaf	11,644	8,267	-5%	49%	71	1.4
 Green Thumb	9,597	7,418	4%	52%	912	1.3
Average	4,352	3,666	6%	45%	83	1.2
Median	2,463	1,648	-5%	48%	0	1.3
 STENOCARE®	51	6	154%	n/a	-10	9.0

Valuation

When looking at the larger, more mature North American companies on the previous page, they are valued to a median multiple of P/S 1.3x. However, there are differences between these companies and STENOCARE that should be taken into consideration. STENOCARE is expected to show a stronger revenue growth during our forecast period, where the North American companies are reporting a revenue growth of -5% Y-Y (median), compared to an estimated CAGR of 78% for STENOCARE in 2024-2028E, which motivates a higher multiple for STENOCARE. In the peer group, some companies have recently started to show profitability on an EBIT level, like STENOCARE the previous two quarters, while some remain unprofitable, hence the profitability motivates a small valuation premium according to Analyst Group. Moreover, the peer group are larger companies both regarding Market Cap and revenue, which motivates a valuation discount to the applied multiple for STENOCARE. However, all in all, Analyst Group believes that a higher multiple than the North American Industry group is justified for STENOCARE, due to higher growth expectations.

As earlier mentioned, we see good sales potential in the Astrum oil, given the several benefits it offers to the industry. Given a successful launch of the product and as more players within the industry recognize the advantages of the product, it is believed that the product could attract interest from larger market players. At such a point, Analyst Group views it as a possibility that STENOCARE may become attractive for a potential acquisition by a larger industry player. For example, we have historically seen larger North American companies acquire smaller European firms to expand into new markets. In 2024, the Canadian cannabis company Curaleaf acquired Can4Med, a pharmaceutical wholesaler specializing in the acquisition, registration, and distribution of medical cannabis and products containing THC and other cannabinoids in Poland. The European medical cannabis market is a relatively young and fragmented market with several smaller players, which may open opportunities for market consolidation.

Taking both the comparison with the younger, more immature companies on the European market, and the more mature, larger companies on the North American market, as well as the possibility for acquisition into consideration, Analyst Group believes a target multiple of P/S 3x on estimated sales during 2027 is reasonable. This represents a higher multiple compared to our latest equity research report (2.8x), which is justified by the upward revision of our growth and profitability assumptions following the Q3-25 report. The report demonstrated strong sales momentum combined with effective cost control for the second consecutive quarter, resulting in improved profitability and a positive operating margin.

A target multiple of 3x on 2027's estimated revenues of DKK 17.2m corresponds to a Market Cap of DKK 51.7m. To make up for uncertainties in the forecasts, given that STENOCARE is yet to scale up sales, investors are likely to demand a high required rate of return, why a discount rate of 14% is applied. Based on a company value of DKK 51.7m in 2027, and the discount rate of 14%, a present value per share of DKK 1.01 is derived in a Base scenario.

DKK 1.01
PER SHARE IN A
BASE SCENARIO

Bull & Bear

Bull Scenario

The following is a selection of potential value drivers in a Bull scenario:

- More doctors prescribe medical cannabis oil products as the advantages becomes more obvious for the health care industry operating within STENOCARE's markets as well as a decreased stigma around medical cannabis through deregulation. Moreover, the Company's IT-platform for online clinics is expected to be a driver of increased prescriptions, as doctors can reach patients more easily.
- STENOCARE's premium product Astrum oil is well-received in the market, with the healthcare industry quickly recognizing the benefits and prescribing larger volumes of the product, which is expected to have a significant impact on sales in 2026. Germany and Australia are expected to be the most important drivers, large markets that currently grows rapidly.
- The Astrum oil is expected to get approved in additional markets globally and enable partnerships with big pharma companies for sales of STENOCARE's products.
- Given a discount rate of 14% and a target multiple of P/S 3.7x on estimated sales of DKK 25m in 2027 in a Bull scenario, a potential present value per share of DKK 1.81 is derived.

DKK 1.81
PER SHARE IN A
BULL SCENARIO

Bear Scenario


The following is a selection of potential factors in a Bear scenario:

- STENOCARE is still in the early stages of the Company's scale-up, which comes with uncertainties. In a Bear scenario, doctors' skepticism against medical cannabis turns out to be persistent, regardless if it is an oil product or not, resulting in fewer patients being prescribed with the products, hence, lower revenue growth for STENOCARE.
- In a Bear scenario, the premium product Astrum oil receives a cooler reception than expected from the industry, leading to a lack of significant sales for the product, which impacts STENOCARE's anticipated future earnings and prolong the time for reaching higher profitability.
- Due to lower revenue growth positive cash flow is expected only at a later stage. Hence, additional external capital raising is needed during the forecast period to fund the operations until positive cash flow is reached, which may incur under unfavorable terms in a scenario of a challenging market environment.
- In a Bear scenario, a lower target multiple is justified, as lower growth and profitability is expected, why a target multiple of P/S 1.8x is applied on 2027 estimated sales of DKK 7.6m. This, in combination with a discount rate of 14%, results in a potential present value per share of DKK 0.27.

DKK 0.27
PER SHARE IN A
BEAR SCENARIO

Illustration of Potential Valuation in a Bull and Bear Scenario.

Value per share Bull and Bear scenario



Source: Analyst Group estimates

Management & Board



Thomas Skovlund Schnegelsberg, CEO and Co-founder

Thomas has been CEO since STENOCARE was founded in 2017 and was also a co-founder of the Company. He holds a Master of Science in Economics and Business Administration from Copenhagen Business School. Previous experiences consist of senior leadership roles at Microsoft in Denmark, Nordic, the UK, and Europe. Thomas has also been a board member at Lauritz.com. *Thomas owns shares through SC-Founders Holding ApS who holds 4,871,022 (12.7%).*



Rolf Steno, CCO, Co-founder and Member of the Board

Rolf has been CCO since STENOCARE was founded in 2017 and was also a co-founder of the Company. He has been CEO at LFP Scandinavia for 14 years as well as a Business Development manager at Techsage, where Rolf was the inventor and partial patent holder of the IP to the Spinjet (spinjet.com). *Rolf owns shares through SC-Founders Holding ApS who holds 4,871,022 (12.7%).*



Peter Bugge Johansen, CFO

Peter has been CFO since 2018 and holds a Master of Science in Economics and Auditing from Copenhagen Business School. Previous experience includes 20 years at Interdan Holding A/S as first CFO and later CEO, 3 years as Tax Manager at A.P. Møller-Mærsk and 14 years as auditor at Deloitte. Though his career, Peter has acquired knowledge in financial and strategic issues such as financing, internal and external reporting, asset management, group structure and mergers and acquisitions. *Peter owns 125,990 shares (0.3%) and have 6,800 remaining of a 5-year options program to receive up to 34,000 shares.*



Marianne Wier, Chairman of the Board

Marianne has been chairman of the board since 2018, holds a law degree from University of Copenhagen and has a background as a lawyer. Today, Marianne is CEO at Taksatorringen, and previous experiences include COO at Topdanmark, President and Attorney at Johan Schlutter Law Firm, Group Public Affairs Manager at Danske Bank, and Corporate & Government Affairs Manager at Microsoft Denmark. *Marianne owns 57,976 shares (0.2%).*



Søren Melsing Frederiksen, Member of the Board

Søren has been a member of the board since 2018 and holds a chemical engineering bachelor and a Master of Industrial Drug Development (MIND) from University of Copenhagen. Today, Søren is Vice President, Commercial Rx and Product Development at Orifarm Healthcare A/S and previous experience ranges from R&D, project management, sales management, and product launch. *Søren owns 107,839 shares (0.3%) through SML Holding ApS.*



Jeppe Bo Petersen, Member of the Board

Jeppe has been a member of the board since 2018 and is currently Group CFO at Habitus. Previous roles include CEO at Olivia Danmark A/S and CFO at, for instance, Valad Europe A/S and Nordicom A/S. He has 30 years of experience in the field of economics. *Jeppe owns 1,667 shares (0.0%)*






Henrik Elbæk Pedersen, Member of the Board

Henrik is currently the CEO of Danisense A/S and has built a distinguished career with expertise in business innovation, global B2B sales, and marketing. Previous experience include General Manager on LEM Danfysik A/S and Director Product Management on GN Netcom. *Henrik owns 4,461,452 shares through HHTM ApS (11.6%)*

Appendix

Base scenario (DKKkm)	2023A	2024A	2025E	2026E	2027E	2028E
Net Sales	4.0	2.2	6.5	12.9	17.2	22.4
Other income	0.0	0.0	0.0	0.0	0.0	0.0
Total income	4.0	2.2	6.5	12.9	17.2	22.4
Other external expenses	-10.2	-7.7	-5.2	-8.2	-11.1	-14.1
Personnel expenses	-6.4	-5.8	-3.0	-3.2	-3.6	-4.3
Special items	0.0	-13.1	0.0	0.0	0.0	0.0
EBITDA	-12.6	-24.2	-1.6	1.5	2.5	4.1
EBITDA margin	-315%	-1086%	-25%	11%	14%	18%
Depreciation of tangible assets	-3.4	-8.9	-0.1	-0.1	-0.1	-0.1
EBIT	-15.9	-33.1	-1.7	1.4	2.4	4.0
EBIT margin	-399%	-1483%	-26%	11%	14%	18%
Financial income	0.0	0.0	0.0	0.0	0.0	0.0
Financial expenses	-2.9	-1.5	-0.6	-0.3	-0.1	-0.1
EBT	-18.8	-34.6	-2.3	1.2	2.4	4.0
Tax	1.3	0.1	0.0	-0.3	-0.6	-1.0
Net result	-17.6	-34.5	-2.3	0.9	1.8	3.0
Net Margin	-440%	-1545%	-36%	7%	10%	13%
Shares outstanding (millions)	38.4	38.4	38.4	38.4	38.4	38.4
Earnings per share (EPS)	neg.	neg.	neg.	0.0	0.0	0.1

■ Net Sales




Appendix


Bull scenario (DKKm)	2023A	2024A	2025E	2026E	2027E	2028E
Net Sales	4.0	2.2	7.5	15.9	25.0	32.7
Other income	0.0	0.0	0.0	0.0	0.0	0.0
Total income	4.0	2.2	7.5	15.9	25.0	32.7
Other external expenses	-10.2	-7.7	-5.8	-9.0	-13.5	-16.8
Personnel expenses	-6.4	-5.8	-3.2	-4.0	-5.4	-6.2
Special Items	0.0	-13.1	0.0	0.0	0.0	0.0
EBITDA	-12.6	-24.2	-1.5	2.9	6.1	9.7
EBITDA margin	-315%	-1086%	-20%	18%	24%	30%
Depreciation of tangible assets	-3.4	-8.9	-0.1	-0.1	-0.1	-0.1
EBIT	-15.9	-33.1	-1.6	2.8	6.0	9.7
EBIT margin	-399%	-1483%	-21%	18%	24%	30%
Financial income	0.0	0.0	0.0	0.0	0.0	0.0
Financial expenses	-2.9	-1.5	-0.6	-0.3	-0.1	-0.1
EBT	-18.8	-34.6	-2.2	2.6	6.0	9.6
Tax	1.3	0.1	0.0	-0.6	-1.5	-2.4
Net result	-17.6	-34.5	-2.2	1.9	4.5	7.3
Net margin	-440%	-1545%	-29%	12%	18%	22%
Shares outstanding (millions)	38.4	38.4	38.4	38.4	38.4	38.4
Earnings per share (EPS)	neg.	neg.	neg.	0.1	0.1	0.2

■ Net Sales


DKKm




DKKm

 ■ Other external expenses
 ■ Personnel expenses
 ■ Depreciation of tangible assets


DKKm

 ■ EBITDA
 - - - EBITDA margin


DKKm


 ■ EBIT
 - - - EBIT margin


Appendix


Bear scenario (DKKm)	2023A	2024A	2025E	2026E	2027E	2028E
Net Sales	4.0	2.2	5.1	6.0	7.6	9.2
Other income	0.0	0.0	0.0	0.0	0.0	0.0
Total income	4.0	2.2	5.1	6.0	7.6	9.2
Other external expenses	-10.2	-7.7	-4.6	-5.0	-5.4	-6.0
Personnel expenses	-6.4	-5.8	-2.9	-3.0	-3.2	-3.4
Special Items	0.0	-13.1	0.0	0.0	0.0	0.0
EBITDA	-12.6	-24.2	-2.4	-2.0	-1.0	-0.1
EBITDA margin	-315%	-1086%	-47%	-32%	-14%	-1%
Depreciation of tangible assets	-3.4	-8.9	-0.1	-0.1	-0.1	-0.1
EBIT	-15.9	-33.1	-2.4	-2.0	-1.1	-0.2
EBIT margin	-399%	-1483%	-48%	-34%	-15%	-2%
Financial income	0.0	0.0	0.0	0.0	0.0	0.0
Financial expenses	-2.9	-1.5	-0.6	-0.3	-0.1	-0.1
EBT	-18.8	-34.6	-3.1	-2.2	-1.1	-0.2
Tax	1.3	0.1	0.0	0.0	0.0	0.0
Net result	-17.6	-34.5	-3.1	-2.2	-1.1	-0.2
Net margin	-440%	-1545%	-60%	-37%	-15%	-2%
Shares outstanding (millions)	38.4	38.4	38.4	38.4	38.4	38.4
Earnings per share (EPS)	neg.	neg.	neg.	neg.	neg.	neg.

■ Net Sales


DKKm




DKKm



DKKm



DKKm



Disclaimer

These analyses, documents and any other information originating from AG Equity Research AB (Henceforth "AG") are created for information purposes only, for general dissipation and are not intended to be advisory. The information in the analysis is based on sources, data and persons which AG believes to be reliable. AG can never guarantee the accuracy of the information. The forward-looking information found in this analysis are based on assumptions about the future, and are therefore uncertain by nature and using information found in the analysis should therefore be done with care. Furthermore, AG can never guarantee that the projections and forward-looking statements will be fulfilled to any extent. This means that any investment decisions based on information from AG, any employee or person related to AG are to be regarded to be made independently by the investor. These analyses, documents and any other information derived from AG is intended to be one of several tools involved in investment decisions regarding all forms of investments regardless of the type of investment involved. Investors are urged to supplement with additional relevant data and information, as well as consulting a financial adviser prior to any investment decision. AG disclaims all liability for any loss or damage of any kind that may be based on the use of analyzes, documents and any other information derived from AG.

Conflicts of Interest and impartiality

To ensure AG's independence, AG has established compliance rules for analysts. In addition, all analysts have signed an agreement in which they are required to report any and all conflicts of interest. These terms have been designed to ensure that *COMMISSION DELEGATED REGULATION (EU) 2016/958 of 9 March 2016, supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest*. Compliance policy: <https://analystgroup.se/interna-regler-ansvarsbegransning/> (Swedish)

Other

This analysis is a task analysis. This means Analyst Group has received payment for doing the analysis. The Principal, **STENOCARE A/S** (furthermore "the Company") has had no opportunity to influence the parts where Analyst Group has had opinions about the Company's future valuation or anything that could constitute an objective assessment.

The parts that the Company has been able to influence are the parts that are purely factual and objective.

The analyst does not own shares in the Company.

This analysis is copyright protected by law © AG Equity Research AB (2014-2025). Sharing, dissemination or equivalent action to a third party is permitted provided that the analysis is shared unchanged.